Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.

Abstract

Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors
  • Antibodies, Viral / biosynthesis*
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology
  • COVID-19 / complications
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / immunology*
  • Follow-Up Studies
  • Humans
  • Immunization, Secondary*
  • Immunocompromised Host
  • Immunogenicity, Vaccine
  • Immunoglobulin G / biosynthesis*
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Neoplasms / complications
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Prospective Studies
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Rituximab / adverse effects
  • Rituximab / therapeutic use
  • SARS-CoV-2 / immunology*
  • Seroconversion
  • Spike Glycoprotein, Coronavirus / immunology
  • Vaccination

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Protein Kinase Inhibitors
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Rituximab
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human